Pharmaceutical

GSK acquires efimosfermin alfa from Boston Pharma for $2bn

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease, from Boston Pharmaceuticals

Jul 9, 2025 - 06:00
GSK acquires efimosfermin alfa from Boston Pharma for $2bn
GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease, from Boston Pharmaceuticals
Read the original article

Tags:

Previous Article

Swissmedic approves Novartis’ malaria medicine for babies

Next Article

FDA approves KalVista’s Ekterly for hereditary angioedema

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech   

Gilead adds investigational HIV vaccine to its portfoli...

Nov 27, 2024

Kellogg’s is going to war over Mexico’s nutrition label rules. A similar fight is coming to the U.S.

Kellogg’s is going to war over Mexico’s nutrition label...

Aug 21, 2023

STAT+: House transparency, PBM reform bill gains bipartisan support

STAT+: House transparency, PBM reform bill gains bipart...

Sep 8, 2023